Erratum: Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial (The Lancet (2018) 391(10131) (1683–1692) (S0140673618302952) (10.1016/S0140-6736(18)30295-2));Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial

The Lancet

Volumn 391, Issue 10131, 2018, Pages 1683-1692

  Blumberger, Daniel M ^a,b,c   Vila Rodriguez, Fidel ^d   Thorpe, Kevin E ^c,e,f   Feffer, Kfir ^g,h   Noda, Yoshihiro ⁱ   Giacobbe, Peter ^b,j,k   Knyahnytska, Yuliya ^a,b   Kennedy, Sidney H ^b,c,f,l   Lam, Raymond W ^d   Daskalakis, Zafiris J ^a,b,c   Downar, Jonathan ^b,c,k,l  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g SHALVATA MENTAL HEALTH CENTER   (Israel)

^h TEL AVIV UNIVERSITY   (Israel)

ⁱ KEIO UNIVERSITY   (Japan)

^j SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^k UNIVERSITY HEALTH NETWORK   (Canada)

^l UNIVERSITY HEALTH NETWORK   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABNORMAL SENSATION; ADULT; AGED; AGITATION; ANXIETY; ARTICLE; BACKACHE; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIZZINESS; DORSOLATERAL PREFRONTAL CORTEX; FATIGUE; FEMALE; HEADACHE; HUMAN; INSOMNIA; INTERMETHOD COMPARISON; INTERMITTENT THETA BURST STIMULATION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MIGRAINE AURA; MULTICENTER STUDY; NAUSEA; NECK PAIN; PATIENT DROPOUT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION; SAFETY; SIDE EFFECT; TINNITUS; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESISTANT DEPRESSION; VOMITING; CANADA; CLASSIFICATION; CLINICAL TRIAL; COMPARATIVE STUDY; DEPRESSION; EPIDEMIOLOGY; MIDDLE AGED; NOCICEPTION; OUTCOME ASSESSMENT; PHYSIOLOGY; PREFRONTAL CORTEX; PROCEDURES; PSYCHOLOGY; THETA RHYTHM; TRENDS;

ANTIDEPRESSANT AGENT;

ADULT; ANTIDEPRESSIVE AGENTS; CANADA; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PAIN PERCEPTION; PREFRONTAL CORTEX; THETA RHYTHM; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME;

EID: 85046089770     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(18)31323-0     Document Type: Erratum

References (46)

1. Murray, CJ, Vos, T, Lozano, R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2197–2223.
2. Rush, AJ, Kraemer, HC, Sackeim, HA, et al. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology 31 (2006), 1841–1853.
3. Lisanby, SH, Noninvasive brain stimulation for depression—the devil is in the dosing. N Engl J Med 376 (2017), 2593–2594.
4. George, MS, Wassermann, EM, Williams, WA, et al. Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. Neuroreport 6 (1995), 1853–1856.
5. Pascual-Leone, A, Rubio, B, Pallardó, F, Catalá, MD, Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. Lancet 348 (1996), 233–237.
6. George, MS, Lisanby, SH, Avery, D, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry 67 (2010), 507–516.
7. O'Reardon, JP, Solvason, HB, Janicak, PG, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry 62 (2007), 1208–1216.
8. Brunoni, AR, Chaimani, A, Moffa, AH, et al. Repetitive transcranial magnetic stimulation for the acute treatment of major depressive episodes: a systematic review with network meta-analysis. JAMA Psychiatry 74 (2017), 143–152.
9. Huang, YZ, Edwards, MJ, Rounis, E, Bhatia, KP, Rothwell, JC, Theta burst stimulation of the human motor cortex. Neuron 45 (2005), 201–206.
10. Suppa, A, Huang, YZ, Funke, K, et al. Ten years of theta burst stimulation in humans: established knowledge, unknowns and prospects. Brain Stimul 9 (2016), 323–335.
11. Di Lazzaro, V, Dileone, M, Pilato, F, et al. Modulation of motor cortex neuronal networks by rTMS: comparison of local and remote effects of six different protocols of stimulation. J Neurophysiol 105 (2011), 2150–2156.
12. Chistyakov, AV, Rubicsek, O, Kaplan, B, Zaaroor, M, Klein, E, Safety, tolerability and preliminary evidence for antidepressant efficacy of theta-burst transcranial magnetic stimulation in patients with major depression. Int J Neuropsychopharmacol 13 (2010), 387–393.
13. Holzer, M, Padberg, F, Intermittent theta burst stimulation (iTBS) ameliorates therapy-resistant depression: a case series. Brain Stimul 3 (2010), 181–183.
14. Li, CT, Chen, MH, Juan, CH, et al. Efficacy of prefrontal theta-burst stimulation in refractory depression: a randomized sham-controlled study. Brain 137 (2014), 2088–2098.
15. Berlim, MT, McGirr, A, Rodrigues Dos Santos, N, Tremblay, S, Martins, R, Efficacy of theta burst stimulation (TBS) for major depression: an exploratory meta-analysis of randomized and sham-controlled trials. J Psychiatr Res 90 (2017), 102–109.
16. Hamilton, M, Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6 (1967), 278–296.
17. Oquendo, MA, Baca-Garcia, E, Kartachov, A, et al. A computer algorithm for calculating the adequacy of antidepressant treatment in unipolar and bipolar depression. J Clin Psychiatry 64 (2003), 825–833.
18. Sackeim, HA, Prudic, J, Devanand, DP, Decina, P, Kerr, B, Malitz, S, The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression. J Clin Psychopharmacol 10 (1990), 96–104.
19. Fox, MD, Buckner, RL, White, MP, Greicius, MD, Pascual-Leone, A, Efficacy of transcranial magnetic stimulation targets for depression is related to intrinsic functional connectivity with the subgenual cingulate. Biol Psychiatry 72 (2012), 595–603.
20. McClintock, SM, Reti, IM, Carpenter, LL, et al. Consensus recommendations for the clinical application of repetitive transcranial magnetic stimulation (rTMS) in the treatment of depression. J Clin Psychiatry, 79, 2017, 16cs10905.
21. Rush, AJ, Giles, DE, Schlesser, MA, Fulton, CL, Weissenburger, J, Burns, C, The Inventory for Depressive Symptomatology (IDS): preliminary findings. Psychiatry Res 18 (1986), 65–87.
22. Derogatis, LR, Melisaratos, N, The Brief Symptom Inventory: an introductory report. Psychol Med 13 (1983), 595–605.
23. Rush, AJ, Trivedi, MH, Ibrahim, HM, et al. The 16-item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): A psychometric evaluation in patients with chronic major depression. Biol Psychiatry 54 (2003), 573–583.
24. Borckardt, JJ, Nahas, ZH, Teal, J, et al. The painfulness of active, but not sham, transcranial magnetic stimulation decreases rapidly over time: results from the double-blind phase of the OPT-TMS Trial. Brain Stimul 6 (2013), 925–928.
25. Fournier, JC, DeRubeis, RJ, Hollon, SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 303 (2010), 47–53.
26. National Collaborating Centre for Mental Health, National Institute for Health & Clinical Excellence. Depression in adults with a chronic physical health problem: treatment and management. National clinical practice guideline 91. 2010, British Psychological Society, The Royal College of Psychiatrists, London.
27. Fitzgerald, PB, Benitez, J, de Castella, A, Daskalakis, ZJ, Brown, TL, Kulkarni, J, A randomized, controlled trial of sequential bilateral repetitive transcranial magnetic stimulation for treatment-resistant depression. Am J Psychiatry 163 (2006), 88–94.
28. Fitzgerald, PB, Hoy, K, Gunewardene, R, et al. A randomized trial of unilateral and bilateral prefrontal cortex transcranial magnetic stimulation in treatment-resistant major depression. Psychol Med 41 (2011), 1187–1196.
29. Gaynes, BN, Lloyd, SW, Lux, L, et al. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis. J Clin Psychiatry 75 (2014), 477–489.
30. Jones, B, Jarvis, P, Lewis, JA, Ebbutt, AF, Trials to assess equivalence: the importance of rigorous methods. BMJ 313 (1996), 36–39.
31. Trivedi, MH, Fava, M, Wisniewski, SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 354 (2006), 1243–1252.
32. Rush, AJ, Trivedi, MH, Wisniewski, SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 354 (2006), 1231–1242.
33. Mauri, L, D'Agostino, RB Sr, Challenges in the design and interpretation of noninferiority trials. N Engl J Med 377 (2017), 1357–1367.
34. Drysdale, AT, Grosenick, L, Downar, J, et al. Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nat Med 23 (2017), 28–38.
35. Cipriani, A, Furukawa, TA, Salanti, G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373 (2009), 746–758.
36. Gamboa, OL, Antal, A, Moliadze, V, Paulus, W, Simply longer is not better: reversal of theta burst after-effect with prolonged stimulation. Exp Brain Res 204 (2010), 181–187.
37. Fregni, F, Marcolin, MA, Myczkowski, M, et al. Predictors of antidepressant response in clinical trials of transcranial magnetic stimulation. Int J Neuropsychopharmacol 9 (2006), 641–654.
38. Milev, RV, Giacobbe, P, Kennedy, SH, et al. Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 4. Neurostimulation treatments. Can J Psychiatry 61 (2016), 561–575.
39. Rossi, S, Hallett, M, Rossini, PM, Pascual-Leone, A, Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol 120 (2009), 2008–2039.
40. Bakker, N, Shahab, S, Giacobbe, P, et al. rTMS of the dorsomedial prefrontal cortex for major depression: safety, tolerability, effectiveness, and outcome predictors for 10 Hz versus intermittent theta-burst stimulation. Brain Stimul 8 (2015), 208–215.
41. Downar, J, Geraci, J, Salomons, TV, et al. Anhedonia and reward-circuit connectivity distinguish nonresponders from responders to dorsomedial prefrontal repetitive transcranial magnetic stimulation in major depression. Biol Psychiatry 76 (2014), 176–185.
42. Arana, AB, Borckardt, JJ, Ricci, R, et al. Focal electrical stimulation as a sham control for repetitive transcranial magnetic stimulation: does it truly mimic the cutaneous sensation and pain of active prefrontal repetitive transcranial magnetic stimulation?. Brain Stimul 1 (2008), 44–51.
43. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Non-inferiority clinical trials to establish effectiveness: guidance for industry. https://www.fda.gov/downloads/Drugs/Guidances/UCM202140.pdf, November, 2016. (Accessed 10 December 2017)
44. Mir-Moghtadaei, A, Caballero, R, Fried, P, et al. Concordance between BeamF3 and MRI-neuronavigated target sites for repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex. Brain Stimul 8 (2015), 965–973.
45. Baeken, C, Vanderhasselt, MA, Remue, J, et al. Intensive HF-rTMS treatment in refractory medication-resistant unipolar depressed patients. J Affect Disord 151 (2013), 625–631.
46. Duprat, R, Desmyter, S, Rudi de, R, et al. Accelerated intermittent theta burst stimulation treatment in medication-resistant major depression: a fast road to remission?. J Affect Disord 200 (2016), 6–14.